SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy

In the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an up...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartsch, Rupert, Bergen, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132803/
https://www.ncbi.nlm.nih.gov/pubmed/30220927
http://dx.doi.org/10.1007/s12254-018-0430-0
_version_ 1783354389576024064
author Bartsch, Rupert
Bergen, Elisabeth
author_facet Bartsch, Rupert
Bergen, Elisabeth
author_sort Bartsch, Rupert
collection PubMed
description In the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy.
format Online
Article
Text
id pubmed-6132803
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-61328032018-09-13 SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy Bartsch, Rupert Bergen, Elisabeth Memo Short Review In the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy. Springer Vienna 2018-08-17 2018 /pmc/articles/PMC6132803/ /pubmed/30220927 http://dx.doi.org/10.1007/s12254-018-0430-0 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Bartsch, Rupert
Bergen, Elisabeth
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
title SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
title_full SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
title_fullStr SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
title_full_unstemmed SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
title_short SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
title_sort sabcs 2017: update on chemotherapy, targeted therapy, and immunotherapy
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132803/
https://www.ncbi.nlm.nih.gov/pubmed/30220927
http://dx.doi.org/10.1007/s12254-018-0430-0
work_keys_str_mv AT bartschrupert sabcs2017updateonchemotherapytargetedtherapyandimmunotherapy
AT bergenelisabeth sabcs2017updateonchemotherapytargetedtherapyandimmunotherapy

Ejemplares similares